These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6376571)

  • 1. Effect of a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on the growth of mouse skin carcinoma in the rapid growing stage.
    Ohkoshi M; Fujii S
    J Dermatol; 1984 Feb; 11(1):21-4. PubMed ID: 6376571
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of oral administration of protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on the growth of 3-methylcholanthrene-induced carcinoma in mice.
    Ohkoshi M; Fujii S
    Gan; 1982 Feb; 73(1):108-10. PubMed ID: 7117738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate.
    Ohkoshi M
    Gan; 1981 Dec; 72(6):959-64. PubMed ID: 7341342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin.
    Ohkoshi M; Fujii S
    J Natl Cancer Inst; 1983 Nov; 71(5):1053-7. PubMed ID: 6580482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma.
    Ohkoshi M; Oka T
    J Maxillofac Surg; 1984 Aug; 12(4):148-52. PubMed ID: 6590712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma.
    Ohkoshi M; Akagawa T; Nakajima M
    Anticancer Res; 1993; 13(4):963-6. PubMed ID: 8352567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protease inhibitors as anticancer chemotherapy--experimental and clinical studies].
    Ohkoshi M
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):417-30. PubMed ID: 7887633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal absorption of N,N'-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy) phenylacetate methanesulfonate in rats.
    Nishihata T; Saitoh Y; Sakai K
    Chem Pharm Bull (Tokyo); 1988 Jul; 36(7):2544-50. PubMed ID: 3240476
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhancement of small intestinal absorption of N,N'-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy) phenylacetate methanesulfonate (FOY305) in rats.
    Nishihata T; Yoshitomi H; Ikawa C; Sakai K
    Chem Pharm Bull (Tokyo); 1988 Jul; 36(7):2703-7. PubMed ID: 3240495
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of camostat mesilate on persistent proteinuria of IgA nephropathy.
    Matsubara M; Taguma Y; Saito T; Yoshinaga K
    Nephron; 1992; 60(2):244-5. PubMed ID: 1553016
    [No Abstract]   [Full Text] [Related]  

  • 11. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403.
    Ohkoshi M; Okuda S
    Anticancer Res; 2002; 22(2A):821-3. PubMed ID: 12014657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effective use of camostat mesilate for chronic disseminated intravascular coagulation complicated by thoracoabdominal aortic aneurysm].
    Yoneda K; Amano I; Tanaka H; Yagi H; Tsukaguchi N; Morii T; Narita N
    Rinsho Ketsueki; 2001 Jan; 42(1):30-4. PubMed ID: 11235131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A proteinase inhibitor reduces proteinuria in nephrotic syndrome.
    Makino H; Onbe T; Kumagai I; Murakami K; Ota Z
    Am J Nephrol; 1991; 11(2):164-5. PubMed ID: 1951480
    [No Abstract]   [Full Text] [Related]  

  • 14. Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate.
    Ikeda S; Manabe M; Muramatsu T; Takamori K; Ogawa H
    J Am Acad Dermatol; 1988 Jun; 18(6):1246-52. PubMed ID: 3385039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic versus natural protease inhibitors in acute experimental pancreatitis.
    Lankisch PG; Pohl U; Otto J
    Dig Dis Sci; 1988 Nov; 33(11):1497-8. PubMed ID: 3180989
    [No Abstract]   [Full Text] [Related]  

  • 16. Subcutaneous administration of the synthetic trypsin inhibitor Foy-305 induces hypertrophy of the exocrine pancreas.
    Wereszczyńska-Siemiatkowska U; Pohl U; Otto J; Lankisch PG
    Digestion; 1987; 37(3):144-8. PubMed ID: 2443410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aprotinin on growth of 3-methylcholanthrene-induced squamous cell-carcinoma in mice.
    Ohkoshi M
    Gan; 1980 Apr; 71(2):246-50. PubMed ID: 6162702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of camostat mesilate on puromycin aminonucleoside nephrotic rats.
    Suzuki J; Suzuki S; Nozawa R; Kumaki S; Kume K; Higuchi E; Kamiyama S; Ohara N; Yugeta E; Kato K
    Fukushima J Med Sci; 1988 Jun; 34(1):21-5. PubMed ID: 3254858
    [No Abstract]   [Full Text] [Related]  

  • 19. [Influences of polychlorinated biphenyl's (PCB) and PCB-like chemicals on 20-methylcholanthrene-induced mouse skin carcinogenesis].
    Hori M; Fujita K; Yamashiro K; Toriyama F; Hirose R; Shukuwa T; Toyoshima H; Yoshida H
    Fukuoka Igaku Zasshi; 1985 May; 76(5):208-14. PubMed ID: 3930370
    [No Abstract]   [Full Text] [Related]  

  • 20. Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate.
    Takahagi S; Shindo H; Watanabe M; Kameyoshi Y; Hide M
    Acta Derm Venereol; 2010 Jul; 90(4):425-6. PubMed ID: 20574618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.